Tag: Sentynl Therapeutics
Sentynl Therapeutics acquires Eiger BioPharmaceuticals’ Zokinvy program to expand portfolio in rare diseases
Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd. (Zydus Group), has closed the acquisition of Eiger BioPharmaceuticals, Inc.'s Zokinvy (lonafarnib) ... Read More
Zydus Group’s Sentynl Therapeutics gains full control of Menkes Disease candidate CUTX-101
Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company under Zydus Lifesciences, Ltd., has finalized an agreement with Cyprium Therapeutics, Inc., a subsidiary of Fortress Biotech, Inc. ... Read More